Impact of genetic variations on side effects from capecitabine in Egyptian cancer patients
Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients
This study is trying to see how a specific genetic change affects side effects from capecitabine in Egyptian cancer patients being treated for colorectal or breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ain Shams University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shibīn al Kawm, Menoufia) |
| Trial ID | NCT06765252 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate how a specific genetic variation in the CES1 gene affects the toxicity experienced by Egyptian patients undergoing capecitabine-based chemotherapy for colorectal or breast cancer. By focusing on the single nucleotide polymorphism rs2244613, the study seeks to understand the variability in drug response among individuals. Participants will be those already receiving capecitabine as part of their standard treatment, allowing for real-world insights into genetic influences on drug toxicity.
Who should consider this trial
Good fit: Ideal candidates include Egyptian adults over 18 years old with breast or colorectal cancer currently undergoing capecitabine-based chemotherapy.
Not a fit: Patients who are not receiving capecitabine or those with gastrointestinal issues that prevent oral medication intake may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment plans that minimize toxicity for cancer patients receiving capecitabine.
How similar studies have performed: While studies on genetic polymorphisms affecting drug toxicity exist, this specific focus on CES1 and capecitabine in an Egyptian population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with breast or colorectal cancer receiving capecitabine-based chemotherapy * Age \> 18 years * ECOG PS 0-2. Exclusion Criteria: * Patients treated with irinotecan * Lack of physical integrity of the upper gastrointestinal tract * Patients with malabsorption syndrome * Patients having inability to take oral medication * Patients with poor performance status * Patients with chronic diarrhea as ulcerative colitis or Crohn's disease
Where this trial is running
Shibīn al Kawm, Menoufia
- Department of Clinical Oncology, Faculty of Medicine, Menoufia University — Shibīn al Kawm, Menoufia, Egypt (Recruiting)
Study contacts
- Study coordinator: Raghad Nassar, Teaching Assistant
- Email: raghad.essam22@pharma.asu.edu.eg
- Phone: 01004446077
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.